FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesGDPR Considerations for DtP Supply Chains
Topics: Regulatory, Supply Chain
Guidance Document
Free
Direct-to-Patient Survey Results Summary
Topics: Health Care, Innovation, Supply Chain
Report
Free
GCSG sponsored study on Patient Receptivity to Direct-to-Patient Shipment in Clinical Trials
Topic: Direct-to-Patient
White Paper
Members
